Wait for US Stock Analytics & Screeners is Over StockAio.com
(Stock All In One) is now Live We hope you will provide us with the same Love & Support as you did for TSR.
Wait for US Stock Analytics is Over StockAio.com
(Stock All In One) is now Live We hope you will provide us with the same Love & Support as you did for TSR.
Fundamental Analysis of Dr Reddys Laboratories (DRREDDY)
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
YoY Net Margin Jump by 80.36%
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 21.43%
All key Trailing Twelve Months Margin growing by 15 %
Steady View
Annual sales of the company is increased for three years in a row
Annual Net Profit in last 3 years is trending up
Steady increase in Total Assets for last 3 Years
EBITDA is continuously increasing for last 3 Years
Company financial liquidity has improved
Book Value in last 3 years is trending up
Good Return On Capital Employed of 18.24
Good Net Margin of 18.28% is achieved by the company
Risky View
Stock Returns is less than Nifty returns for consequitive last three years
Very Low Dividend Yield of 0.870 %
Low Earning Yield of 5.81 %
EPS decline for last four quarters
Terrific Steady Risky Stock View - Fundamental Snapshot
Share Overview
Promoter Owned
26.70 %
Institution Owned
61.30 %
Public/Others
12.00 %
Outstanding Shares
16.61 Cr
Floating Shares
11.85 Cr
Floating / Outstanding
71.37%
Book Value/Share
1402.50
Face value
5.00
Share Holding
Annual Key Income Statement of DRREDDY
Period
31_Mar_2023
31_Mar_2022
Growth
Net Income From Continuing Ops
4470.30
2112.20
111.64 %
Net Income
4507.30
2182.50
106.52 %
Operating Income
8535.70
2506.70
240.52 %
Total Revenue
24669.70
21545.20
14.50 %
Operating Expense
19713.70
19038.50
3.55 %
Interest Expense
142.80
95.80
49.06 %
Tax Expense
1541.20
878.90
75.36 %
Income Before tax
6011.50
2991.10
100.98 %
Gross Profit
20297.20
11384.00
78.30 %
Dividend Paid
-497.90
-414.60
20.09 %
Quarterly Key Income Statement of DRREDDY
Period
31_Mar_2023
31_Dec_2022
Growth
Net Income From Continuing Ops
952.50
1237.90
23.06 %
Net Income
960.10
1243.90
22.82 %
Operating Income
1218.40
1614.80
24.55 %
Total Revenue
6315.20
6789.80
6.99 %
Operating Expense
4781.30
4851.30
1.44 %
Interest Expense
35.40
41.80
15.31 %
Tax Expense
369.00
393.80
6.30 %
Income Before tax
1321.50
1631.70
19.01 %
Gross Profit
3599.70
4788.40
24.82 %
Dividend Paid
0
0
%
Key Balance Sheet Fields
Period
31_Mar_2023
31-Mar-22
Growth
Common Stock
83.30
83.20
0.120 %
Current Liabilities
8572.10
9765.80
12.22 %
Total Liabilities
8999.00
10534.50
14.58 %
Current Assets
20694.20
17782.30
16.38 %
Total Assets
32285.10
29746.90
8.53 %
Working capital
12122.10
8016.50
51.21 %
Accounts Payable
2268.40
2266.20
0.097 %
Inventory
4867.00
5088.40
4.35 %
Net Receivable
7248.50
6676.40
8.57 %
Key Cash Flow Fields
Period
31_Mar_2023
31_Mar_2022
Growth
Cash EPS
344.54
197.58
74.38 %
Cash From Investment Activity
-4137.00
-2638.70
56.78 %
Cash From Financial Activity
-2686.00
-242.20
1009.00 %
Cash Operational Activity
5887.00
2810.80
109.44 %
Net Cash Flow
-936.00
-70.10
1235.24 %
NetIncome
4507.30
2182.50
106.52 %
Capital Expenditure
1886.40
1466.00
28.68 %
Change To Inventory
-265.40
-532.80
50.19 %
About Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets; and collaboration with Shanghai Junshi Biosciences Co., Ltd to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Address : 8-2-337, Road No. 3, Hyderabad, India, 500034
TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, Moving Avg, Chart Patterns, Candlestick and proprietary algorithms.Technical Strength is calculate from 5 Mins Tick to One Month Tick.
TSR Growth analyses dozen of Historical , MRQ, TTM Parameters, Returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential.
TSR Value analyses dozen of Historical , MRQ, TTM Parameters, Returns of Individual Stocks vis-a-vis sector , broad based Index to access its value.
This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback
We are working on fundamental strength also. Please share your views to help shape up the requirement.
